Glycocalyx Integrity Biomarkers in Cardiovascular Health

Abstract

The endothelial glycocalyx is a complex, carbohydrate-rich layer lining the luminal surface of vascular endothelial cells, serving as a crucial regulator of vascular homeostasis. Recent advances underscore the significance of glycocalyx integrity in cardiovascular health, where its disruption is increasingly recognized as an early marker and mediator of vascular dysfunction. Circulating biomarkers reflective of glycocalyx shedding or degradation, such as syndecan-1, heparan sulfate, and hyaluronic acid, have emerged as valuable tools for early detection and risk stratification in various cardiovascular disorders. This review synthesizes current knowledge on the epidemiology, pathophysiology, risk factors, clinical manifestations, diagnostic strategies, and management approaches concerning glycocalyx integrity, focusing on recent evidence and guideline-based recommendations for clinicians.

Introduction

The vascular endothelium forms a dynamic interface between blood and tissue, with the glycocalyx acting as its first line of defense. Composed predominantly of proteoglycans, glycosaminoglycans, and associated plasma proteins, the glycocalyx plays a pivotal role in modulating shear stress, vascular permeability, leukocyte adhesion, and coagulation. Disruption or shedding of the glycocalyx has been implicated in the pathogenesis of a spectrum of cardiovascular diseases, from atherosclerosis to heart failure and acute coronary syndromes. As research progresses, quantification of circulating glycocalyx components is increasingly incorporated into clinical and investigational protocols, offering novel insight into endothelial health and cardiovascular risk.

Epidemiology / Disease Burden

Cardiovascular diseases (CVD) remain the leading cause of morbidity and mortality worldwide, accounting for nearly 18 million deaths annually. The burden is particularly pronounced in populations with metabolic syndrome, diabetes, hypertension, and chronic kidney disease conditions characterized by systemic endothelial dysfunction and heightened vascular risk. Glycocalyx impairment is now recognized as a common denominator in these pathologies, with evidence suggesting that early glycocalyx disruption may precede and predict overt vascular events. Epidemiological studies have demonstrated elevated levels of glycocalyx degradation products in patients with established CVD, suggesting their potential as markers of subclinical disease and predictors of adverse outcomes.

Pathophysiology

The structural integrity of the glycocalyx is maintained by a balance between synthesis and enzymatic degradation. Pathological stimuli including hyperglycemia, oxidative stress, inflammation, and mechanical injury trigger the activation of sheddases such as matrix metalloproteinases and heparanase. These enzymes degrade core glycocalyx components, resulting in the release of syndecan-1, heparan sulfate, and hyaluronic acid into the circulation. Glycocalyx loss leads to increased vascular permeability, dysregulated leukocyte trafficking, platelet adhesion, and prothrombotic states, thereby accelerating the progression of atherosclerosis, microvascular dysfunction, and ischemic injury. In experimental models, restoration of glycocalyx integrity has been shown to reverse some of these pathogenic processes, highlighting its central role in cardiovascular physiology.

Risk Factors

Several modifiable and non-modifiable factors contribute to glycocalyx injury in cardiovascular health. Diabetes mellitus, particularly with poor glycemic control, is associated with chronic glycocalyx degradation due to persistent hyperglycemia and oxidative stress. Hypertension and dyslipidemia exacerbate endothelial injury through augmented shear forces and lipid-induced inflammation. Smoking, systemic infections, and chronic inflammatory states also promote glycocalyx shedding. Aging, genetic predisposition, and exposure to environmental toxins further increase vulnerability. Understanding these risk factors underscores the importance of early intervention and risk modification in preserving vascular health.

Clinical Features

Glycocalyx disruption is largely subclinical in its early stages, but it lays the groundwork for a variety of cardiovascular manifestations. Clinically, patients may present with features of microvascular dysfunction, including impaired vasodilation, tissue edema, and increased susceptibility to thrombosis. In acute settings, such as sepsis or acute myocardial infarction, rapid glycocalyx shedding correlates with disease severity and adverse outcomes. Chronic glycocalyx degradation contributes to the progression of atherosclerotic plaque, heart failure with preserved ejection fraction, and microvascular angina. Recognition of these clinical phenotypes is essential for timely diagnosis and therapeutic intervention.

Diagnosis

Assessment of glycocalyx integrity has evolved with the advent of sensitive biomarkers and imaging modalities. Circulating levels of syndecan-1, heparan sulfate, and hyaluronic acid are the most studied serum markers, correlating with both acute and chronic endothelial injury. Techniques such as sidestream dark field (SDF) imaging and orthogonal polarization spectral (OPS) imaging, though primarily research tools, enable visualization of the sublingual microvascular glycocalyx in vivo. Recent studies suggest that combining biomarker data with functional microvascular assessments enhances early detection and risk prediction in clinical practice. Establishing standardized reference ranges and integrating glycocalyx assessment into routine cardiovascular care remain ongoing challenges.

Treatment & Management

Therapeutic strategies targeting the glycocalyx focus on both prevention of further degradation and restoration of its structure. Optimal management of cardiovascular risk factors particularly glycemic control, blood pressure regulation, and lipid lowering remains the cornerstone of care. Pharmacological agents with endothelial-protective properties, such as statins, angiotensin-converting enzyme inhibitors, and sodium-glucose cotransporter-2 (SGLT2) inhibitors, have demonstrated benefits in preserving or restoring glycocalyx integrity. Adjunctive therapies under investigation include antioxidants, anti-inflammatory agents, and recombinant glycosaminoglycans. Supportive care in acute settings, such as fluid management in sepsis, should aim to avoid further endothelial injury.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in the understanding and therapeutic targeting of the glycocalyx. Novel agents such as sulodexide, a glycosaminoglycan mixture, and recombinant human thrombomodulin are being explored for their potential to repair damaged glycocalyx and mitigate microvascular dysfunction. Advanced imaging and omics-based approaches are elucidating the molecular signatures of glycocalyx injury, paving the way for precision medicine. Large-scale clinical trials are required to validate the clinical utility of glycocalyx biomarkers in routine cardiovascular risk assessment and to establish standardized, evidence-based protocols for intervention.

Guideline Recommendations

Although formal guidelines specific to glycocalyx biomarkers are still evolving, major cardiovascular societies increasingly recognize the importance of endothelial health in risk stratification and management. Current recommendations emphasize aggressive modification of cardiovascular risk factors, early identification of endothelial dysfunction, and adherence to evidence-based pharmacotherapy. Integration of glycocalyx integrity assessment is anticipated as biomarker data and imaging modalities become more widely validated and accessible. Clinicians should remain updated on emerging evidence to inform practice and optimize patient outcomes.

Conclusion

Glycocalyx integrity represents a critical determinant of cardiovascular health, with biomarkers of its disruption offering promising tools for early detection, risk stratification, and therapeutic targeting. Ongoing research is expanding our understanding of the mechanisms underlying glycocalyx injury and repair, while emerging therapies hold potential for reversing microvascular dysfunction. Incorporating glycocalyx assessment into clinical practice may enhance prevention and management strategies for cardiovascular disease, ultimately improving patient outcomes in this high-risk population.